Molbio Diagnostics completed its IPO and trades on BSE/NSE under the ticker MOLBIO. The last mark stands at $1B.
1 valuation. The latest, $1B post-money, was set by the Growth investment in Jan 2022.
Temasek HoldingsLEADMolbio Diagnostics is an Indian molecular diagnostics company headquartered in Verna, Goa, that developed the Truenat platform, a battery-operated, portable real-time PCR system for point-of-care testing. Truenat detects infectious diseases including tuberculosis, HIV, hepatitis, malaria and HPV, and is recognized by the World Health Organization for initial detection of TB and rifampicin resistance.
Founded in 2000, Molbio built the platform through its research subsidiary Bigtec Labs and has installed its technology in more than 85 countries, touching over 40 million lives. In 2025 it became the first private-sector recipient of the Stop TB Partnership's Kochon Prize, the world's largest tuberculosis award.
Molbio Diagnostics trades publicly on BSE/NSE as MOLBIO. A brokerage with access to that exchange can buy the shares.
Index and sector funds may hold Molbio Diagnostics; a fund's latest schedule of investments lists its holdings.
Valuations, rounds and IPO status for every company in the directory — Molbio Diagnostics included.
The closest medical diagnostics / molecular diagnostics peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
Yes. Molbio Diagnostics is listed on BSE/NSE as MOLBIO.
The last valuation is $1B.
Lead investors for each round are in the funding timeline.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
